E

Emcure Pharmaceuticals Ltd
NSE:EMCURE

Watchlist Manager
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Watchlist
Price: 1 456.5 INR 1.46% Market Closed
Market Cap: ₹276.1B

Operating Margin

14%
Current
Improving
by 0.2%
vs 3-y average of 13.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
14%
=
Operating Income
₹11.8B
/
Revenue
₹84.5B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
14%
=
Operating Income
₹11.8B
/
Revenue
₹84.5B

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Emcure Pharmaceuticals Ltd
NSE:EMCURE
276B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Higher than 72% of companies in India
Percentile
72st
Based on 5 437 companies
72st percentile
14%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Emcure Pharmaceuticals Ltd
Glance View

Market Cap
276.1B INR
Industry
Pharmaceuticals

Emcure Pharmaceuticals Ltd. emerged as a prominent player in the Indian pharmaceutical landscape, guided by a commitment to innovation and accessibility. Founded in 1981 by Satish Mehta, the company started as a small-scale manufacturer and has since evolved into a global pharmaceutical powerhouse. Emcure thrives on a multifaceted business model that encompasses the complete pharmaceutical value chain, from research and development to manufacturing and distribution. The company's success rests on its robust portfolio of generics, branded generics, and biopharmaceuticals, which cater to diverse therapeutic areas like cardiology, oncology, gynecology, and infectious diseases. The driving force behind Emcure's financial engine is its ability to balance volume and value. Through a network of state-of-the-art facilities, Emcure sustains a strong presence both domestically and internationally, with exports spanning over 70 countries. The firm capitalizes on economies of scale by leveraging its extensive production infrastructure, allowing it to offer high-quality medications at competitive prices. Furthermore, strategic collaborations and licensing agreements empower Emcure to penetrate new markets and broaden its product offerings. By continually expanding its pipeline and embracing cutting-edge technologies, Emcure not only secures its position in the competitive pharmaceutical industry but also reinforces its mission to deliver affordable healthcare solutions globally.

EMCURE Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
14%
=
Operating Income
₹11.8B
/
Revenue
₹84.5B
What is Emcure Pharmaceuticals Ltd's current Operating Margin?

The current Operating Margin for Emcure Pharmaceuticals Ltd is 14%, which is above its 3-year median of 13.8%.

How has Operating Margin changed over time?

Over the last 1 years, Emcure Pharmaceuticals Ltd’s Operating Margin has increased from 13.7% to 14%. During this period, it reached a low of 13.7% on Dec 31, 2024 and a high of 14% on Jun 30, 2025.

Back to Top